Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: Role of immune responses

Proceedings of the Royal Society B: Biological Sciences

Volumn 277, Issue 1689, 2010, Pages 1875-1880

  Wodarz, Dominik ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer treatment dynamics; Dynamics; Immune system; Mathematical models; Population dynamics

Indexed keywords

CANCER; CORRELATION; DATA SET; DRUG RESISTANCE; HETEROGENEITY; IMMUNE RESPONSE; IMMUNE SYSTEM; NUMERICAL MODEL; POPULATION DYNAMICS; REGROWTH;

EID: 77954324312     PISSN: 09628452     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rspb.2009.2179     Document Type: Conference Paper

References (28)

1. Barnes, E., Harcourt, G., Brown, D., Lucas, M., Phillips, R., Dusheiko, G. & Klenerman, P. 2002 The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 36, 743-754. (doi:10.1053/jhep.2002.35344)
2. Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J. & Deininger, M. W 2006 Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethylN-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108, 2332-2338. (doi:10.1182/blood-2006-02-004580)
3. Calabretta, B. & Perrotti, D. 2004 The biology of CML blast crisis. Blood 103, 4010-4022. (doi:10.1182/blood2003-12-4111)
4. Chen, C. I., Maecker, H. T. & Lee, P. P. 2008 Development and dynamics of robust T-cell responses to CML under imatinib treatment. Blood 111, 5342-5349. (doi:10. 1182/blood-2007-12-128397)
5. Deininger, M. W 2007 Optimizing therapy of chronic myeloid leukemia. Exp. Hematol. 35, 144-154. (doi:10. 1016/j.exphem.2007.01.023)
6. Deininger, M. W. & Druker, B. J. 2003 Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55, 401-423. (doi:10.1124/pr. 55.3.4)
7. Druker, B. J. 2003 Overcoming resistance to imatinib by combining targeted agents. Mol. Cancer Ther 2, 225-226.
8. Druker, B. J. 2004 Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30. (doi:10.1016/ S0065-230X(04)91001-9)
9. Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R. & Scapozza, L. 2003 Molecular mechanisms of resistance to imatinib in Philadelphiachromosome-positive leukaemias. Lancet Oncol. 4, 75-85. (doi:10.1016/S1470-2045(03)00979-3)
10. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N. & Sawyers, C. L. 2001 Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 293, 876-880. (doi:10.1126/science.1062538)
11. Kalams, S. A., Goulder, P. J., Shea, A. K., Jones, N. G., Trocha, A. K., Ogg, G. S. & Walker, B. D. 1999 Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 73, 6721-6728.
12. Kim, P. S., Lee, P. P. & Levy, D. 2008 Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput. Biol. 4, e1000095. (doi:10.1371/journal.pcbi.1000095)
13. Komárova, N. L. & Wodarz, D. 2007 Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2, e990. (doi:10.1371/journal.pone. 0000990)
14. Komarova, N. L., Barnes, E., Klenerman, P. & Wodarz, D. 2003 Boosting immunity by antiviral drug therapy: a simple relationship among timing, efficacy, and success. Proc. Nati Acad. Sci. USA 100, 1855-1860. (doi:10. 1073/pnas.0337483100)
15. Lifson, J. D. et al. 2000 Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient post-inoculation antiretroviral treatment. J. Virol. 74, 2584-2593. (doi:10.1128/JVI.74.6.2584-2593. 2000)
16. Michor, F., Hughes, T. P., Iwasa, Y., Branford, S., Shah, N. P., Sawyers, C. L. & Nowak, M. A. 2005 Dynamics of chronic myeloid leukaemia. Nature 435, 1267-1270. (doi: 10.1038/nature03669)
17. Nardi, V., Azam, M. & Daley, G. Q. 2004 Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35-43. (doi:10.1097/00062752-200401000-00006)
18. Ogg, G. S. et al. 1999 Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797-800.
19. Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M. C. & Loeffler, M. 2006 Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat. Med. 12, 1181-1184. (doi:10.1038/nm1487)
20. Rousselot, P. et al. 2006 Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood 109, 58-60. (doi:10.1182/blood-2006-03-011239)
21. Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. & Sawyers, C. L. 2004 Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401. (doi:10.1126/science.1099480)
22. Shet, A. S., Jahagirdar, B. N. & Verfaillie, C. M. 2002 Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 16, 1402-1411. (doi:10. 1038/sj.leu.2402577)
23. Talpaz, M. et al. 2006 Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl. J. Med. 354, 2531-2541. (doi:10.1056/ NEJMoa055229)
24. Wang, H., Cheng, F., Cuenca, A., Horna, P., Zheng, Z., Bhalla, K. & Sotomayor, E. M. 2005 Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood 105, 1135-1143. (doi:10.1182/blood-2004-01-0027)
25. Weisberg, E., Manley, P. W., Cowan-Jacob, S. W., Hochhaus, A. & Griffin, J. D. 2007 Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer., 345-356. (doi:10.1038/nrc2126)
26. Wodarz, D. 2001 Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. J. Theor. Biol. 213, 447-459. (doi:10.1006/jtbi.2001.2426)
27. Wodarz, D. & Nowak, M. A. 1999 Specific therapy regimes could lead to long-term control of HIV. Proc. Natl Acad. Sci. USA 96, 14 464-14 469. (doi:10.1073/pnas.96.25. 14464)
28. Yoshida, C. & Melo, J. V. 2004 Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinibresistant disease. Int J. Hematol. 79, 420-433. (doi:10. 1532/IJH97.04032)